ClinicalTrials.gg
Not yet recruitingNCT06388538COLD2BUpdated Apr 30, 2024

The COLD2B Multicenter, Two-arm Prospective Cohort Study

An observational study in Acute Diverticulitis, sponsored by Azienda Sanitaria di Firenze. Not yet recruiting at 4 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Azienda Sanitaria di Firenze · Observational

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Since it is still debated whether 2b acute diverticulitis (AD), according to the World Society of Emergency Surgery (WSES) classification, should be initially treated surgically or conservatively, the COLD2B study has been launched to compare the clinical results of both therapeutic regimens in a multi-institutional cohort of prospectively enrolled patients.

The primary aim of the COLD2B (Conservative vs surgical (either Open or Laparoscopic) approach in the emergency management of acute Diverticulitis WSES 2B) study is to develop a model able to predict the length of hospitalization, comparing the management of WSES 2b AD in the emergency setting (conservative versus surgical approach) (primary endpoint of the first arm of the study).

Moreover, the two groups will be compared regarding mortality and morbidity (secondary end-point).

The second arm of the study will consider the population undergoing surgery, develop a model able to predict the length of hospitalization, and compare the open vs laparoscopic approach (primary end-point), and mortality, morbidity, and surgical outcome indices (secondary end-point).

Read the detailed description

The COLD2B study is a national, multi-center, prospective observational study of acutely (unplanned and non-elective presentation to hospital for urgent or emergency reasons) presenting patients to the emergency departments of the participating centers with WSES 2b AD (Distant gas - more than 5 cm from inflamed bowel segment).

The study population includes all consecutive adult patients (≥18 years of age) acutely (unplanned and non-elective presentation to hospital for urgent or emergency reasons) presenting at the participating centers with a clinical and radiological diagnosis of WSES 2b AD for 1 year. According to the different management methods, the cohort will be divided into the following categories:

  1. Conservatively treated, which will include patients treated with medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage) and
  2. Surgically resected, which will be devised into the following sub-categories:

2a) Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure) 2b) Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above The enrollment period and the overall evaluation will last approximately 1 year.

02

Conditions studied

  • Acute Diverticulitis

Browse trials for

Keywords

  • COLD2b
  • acute diverticulitis stage 2B WSES
  • sigmoid acute diverticulitis
  • left-side colonic acute diverticulitis
03

In context

Diverticulitis

125 studies on the registry are indexed under Diverticulitis; 22 are open to participants now.

This study's planned enrollment of 500 is above the median of 275 across 59 observational studies indexed under Diverticulitis.

Browse Diverticulitis studies →

Lead sponsor

Azienda Sanitaria di Firenze is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients affected by WSES 2b acute diverticulitis actively present at participating hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of both sexes, ≥ 18 years old.
  2. Patients with abdominal CT scan diagnosis of colonic Acute Diverticulitis classifiable as WSES 2B, i.e..

    1. thickening and other phlegmon signs of the left-sided colonic wall (mostly sigmoid) associated with the inflammatory involvement of the surrounding tissues, plus
    2. presence of air bubbles distant more than 5 cm from the primary colonic inflammatory localization, plus
    3. absence of conspicuous free fluid collection or pelvic abscess.
  3. Patients fit for surgery.
  4. Patients with colonic diverticulitis on postoperative histological examination.

Exclusion criteria

Exclusion Criteria:

  1. Right-sided or transverse diverticulitis
  2. Concomitant bowel abscess, perforation, or fistula
  3. Radiological drainage
  4. Elective procedures.
  5. Pregnancy or lactation
  6. Patients of both sexes, younger than 18 years of age
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with WSES stage 2b acute diverticulitis

    Patients with WSES stage 2b acute diverticulitis on the left or sigmoid colon acutely presenting to the emergency departments of the participating centers

    Other: Conservative treatment (non-operative treatment) · Other: Surgical treatment (operative treatment)

Interventions

  • OtherConservative treatment (non-operative treatment)

    Conservative treatment consists of medical therapy (see fluid, anti-pain drugs and antibiotics, except for radiologic drainage)

  • OtherSurgical treatment (operative treatment)

    Surgical treatment (operative treatment) is explained as follows: 1. Open surgery management, i.e. traditional open surgery approach with any kind of technique: either reconstructive (with or without ileal/colonic stoma protection) or non-reconstructive (see Hartman procedure) 2. Laparoscopic approach, i.e. emergency laparoscopic resection with the characteristics mentioned above

06

What researchers measure

Primary outcomes

  1. Length of hospital stay in the overall population

    To develop a predictive model for the length of hospital stay (measured in days) taking into account the treatment received in the overall population

    Time frame: 1 year

Secondary outcomes

  1. Morbidity rate for both arms

    To compare morbidity (i.e. medical problems related to the treatment) for both conservative and surgical arms

    Time frame: 1 year

  2. Mortality rate for both arms

    to compare mortality for both conservative and surgical arms

    Time frame: 1 year

  3. Surgical complications rate

    To compare surgical complications rate for the surgical arms (laparoscopy versus open), measured according to Clavien-Dindo Classification (grade 1 to 5)

    Time frame: 1 year

07

Study locations

4 sites
  • Dipartimento di Medicina di Precisione e Rigenerativa e Area Jonica (DiMePRe-J), Universita' di Bari
    Bari, Italy
    • Francesco Paolo Prete · Contact
  • Department of Emergency and Acceptance, Emergency Surgery Unit, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
    Florence, 50134, Italy
    • Carlo Bergamini, MD · Contactdrcarlobergamini@gmail.com · +39(0)557949173
    • Carlo Bergamini · Principal investigator
    • Alessio Giordano · Principal investigator
  • Department of Medicine, Surgery and Health Sciences, University of Trieste
    Trieste, Italy
    • Manuela Mastronardi · Contact
  • Department of General Surgery, PO di Vittorio Veneto (TV), ULSS2 Marca Trevigiana
    Vittorio Veneto, Italy
    • Giulia Montori · Contact
08

References and documents

Publications

  • undefined

Related links

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388538
Lead sponsor
Azienda Sanitaria di Firenze
Responsible party
Alessio Giordano (Principal Investigator, Azienda Sanitaria di Firenze) — Principal investigator
First posted
Apr 29, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
May 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Apr 30, 2024

Study contacts

Carlo Bergamini Carlo Bergamini, M.D.
Contact
drcarlobergamini@gmail.com
0039(0)557949173
Alessio Biagio Giordano Alessio Giordano, MD
Contact
alessio.giordano8@gmail.com
+390557949173

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion